A Novo Nordisk-led study comparing CagriSema, its GLP-1 drug candidate for obesity, found that Eli Lilly’s Zepbound resulted in greater weight loss.
The open-label, head-to-head trial analyzed the average weight loss among adults who received weekly injections of either CagriSema or Zepbound. After 84 weeks, the CagriSema group achieved a 20.2% reduction in weight, compared to the 23.6% weight loss with Zepbound.
Novo Nordisk announced the phase 3 trial results Feb. 23. The trial included 809 adults with obesity and at least one comorbidity, according to the Denmark-based drugmaker.
This trial is part of a multi-part clinical study on CagriSema including about 4,600 adults with obesity or overweight.
In December, Novo Nordisk submitted CagriSema to the FDA for approval, and the drugmaker said a decision is expected by late 2026.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
